Cargando…
Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes
Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by i...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980569/ https://www.ncbi.nlm.nih.gov/pubmed/29575656 http://dx.doi.org/10.1002/psp4.12290 |
_version_ | 1783327900387246080 |
---|---|
author | Wellhagen, Gustaf J. Karlsson, Mats O. Kjellsson, Maria C. |
author_facet | Wellhagen, Gustaf J. Karlsson, Mats O. Kjellsson, Maria C. |
author_sort | Wellhagen, Gustaf J. |
collection | PubMed |
description | Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by investigating four HbA1c models, specifically the ability to identify drug effects (shape, site of action, and power) and simulation properties. All models could identify glucose effect nonlinearities, although for detecting the site of action, a mechanistic glucose model was needed. Power was highest for models using mean plasma glucose to drive HbA1c formation. Insulin contribution to power varied greatly depending on the drug target; it was beneficial only if the drug target was insulin secretion. All investigated models showed good simulation properties. However, extrapolation with the mechanistic model beyond 12 weeks resulted in drug effect overprediction. This investigation aids drug development in decisions regarding model choice if reusing published HbA1c models. |
format | Online Article Text |
id | pubmed-5980569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59805692018-06-01 Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes Wellhagen, Gustaf J. Karlsson, Mats O. Kjellsson, Maria C. CPT Pharmacometrics Syst Pharmacol Research Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by investigating four HbA1c models, specifically the ability to identify drug effects (shape, site of action, and power) and simulation properties. All models could identify glucose effect nonlinearities, although for detecting the site of action, a mechanistic glucose model was needed. Power was highest for models using mean plasma glucose to drive HbA1c formation. Insulin contribution to power varied greatly depending on the drug target; it was beneficial only if the drug target was insulin secretion. All investigated models showed good simulation properties. However, extrapolation with the mechanistic model beyond 12 weeks resulted in drug effect overprediction. This investigation aids drug development in decisions regarding model choice if reusing published HbA1c models. John Wiley and Sons Inc. 2018-03-25 2018-05 /pmc/articles/PMC5980569/ /pubmed/29575656 http://dx.doi.org/10.1002/psp4.12290 Text en © 2018 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Wellhagen, Gustaf J. Karlsson, Mats O. Kjellsson, Maria C. Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title | Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title_full | Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title_fullStr | Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title_full_unstemmed | Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title_short | Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes |
title_sort | comparison of power, prognosis, and extrapolation properties of four population pharmacodynamic models of hba1c for type 2 diabetes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980569/ https://www.ncbi.nlm.nih.gov/pubmed/29575656 http://dx.doi.org/10.1002/psp4.12290 |
work_keys_str_mv | AT wellhagengustafj comparisonofpowerprognosisandextrapolationpropertiesoffourpopulationpharmacodynamicmodelsofhba1cfortype2diabetes AT karlssonmatso comparisonofpowerprognosisandextrapolationpropertiesoffourpopulationpharmacodynamicmodelsofhba1cfortype2diabetes AT kjellssonmariac comparisonofpowerprognosisandextrapolationpropertiesoffourpopulationpharmacodynamicmodelsofhba1cfortype2diabetes |